News | August 12, 2021
Natco Pharma PAT at Rs 75 crore for Q1FY22
The company has strong product launches both in India and overseas
The company has strong product launches both in India and overseas
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
The collaboration will support Canada with direct access to rapid pandemic response capabilities
If approved it will bring a second source of MMR vaccine to the US market
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Subscribe To Our Newsletter & Stay Updated
